From a pharmacological safety perspective, the adverse effect profile of retatrutide based on Phase 1 and Phase 2 clinical trial data (including the NEJM 2023 Phase 2 trial) includes: Gastrointestinal effects: Nausea, vomiting, diarrhoea, and constipation (the most commonly reported side effects in trial participants) Injection site reactions: Redness, swelling, or discomfort at the injection site Cardiovascular effects: Increases in heart rate have been observed in trial participants [21] [22] Hypoglycaemia: Particularly relevant in individuals with diabetes or those taking insulin, sulfonylureas, or other glucose-lowering agents Potential thyroid effects: GLP-1 receptor agonists have been associated with thyroid C-cell changes in rodent studies
Shelf Life Once Opened: Can be used multiple times, but should be discarded if the solution becomes cloudy or after 28 days (per common lab practice)
This trigger injection usually contains an HCG
Implications for dosing frequency Despite the short serum half-life, daily (rather than multiple-times-daily) dosing has been shown adequate in most BPC-157 rodent studies
Peptide Therapy at a Glance EXPECTED RESULTS Enhanced cellular repair, improved hormone balance, increased energy, better sleep, fat loss, and immune support TREATMENT LENGTH Varies daily or weekly administration over 412+ weeks depending on protocol RECOMMENDED SESSIONS Ongoing use for 13 months, with regular monitoring and dose adjustments WHERE IT TREATS Systemic works at the cellular level to support immune, endocrine, metabolic, and neurological systems WHAT IT TREATS Hormone imbalance, weight gain, poor recovery, fatigue, inflammation, aging, low libido, immune dysfunction, and neurological decline TREATMENT COST $350 $1,200/month (depending on the type of peptide and dosing protocol) What is Peptide Therapy
